Treatment of alzheimer's disease and modulation of immune system with .DELTA.5-androstenes
AssigneeHumanetics Corporation
InventorHenry A. Lardy
Life of this patent
Estimating the term…
Abstract
Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
Claims20
A method for treating a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
A method for retarding degeneration of the central nervous system of a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
A method for retarding loss of metal facilities of a mammal with Alzheimer's disease comprising the step of administering to the mammal a therapeutic amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
A method for retarding short term memory loss of a mammal with Alzheimer's disease comprising the step of administering to the mammal an effective amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
A method for retarding the advancement of disorientation in a mammal with Alzheimer's disease comprising the step of administering to the mammal a therapeutic amount of a steroid selected from the group consisting of .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
Dependencies are inferred from the claim text.